HOME >> MEDICINE >> NEWS
New drug to treat enlarged prostate developed at UCL

Millions of men stand to benefit from a discovery by UCL scientists that could provide a breakthrough in the treatment of enlargement of the prostate (BPH). The UCL team has developed a new drug, Rho-kinase inhibitor that, in preliminary tests, has been found to treat the condition by both relaxing the prostate and stopping the growth of cells within it. Their findings are set out in the current issue of the Journal of Urology.

BPH affects approximately 85% of men over the age of 50 and causes frequent urination and irritation due to the obstruction of urine flow. The drugs currently available for treatment of BPH aim to either relax the prostrate or to reduce its size as two separate actions, and also have undesired hormonal effects. These effects, along with the need to take two separate treatments, often lead to problems of patient compliance. The discovery by the UCL scientists is novel in that this new drug can both relax the prostate and stop it from growing, with virtually no hormonal side effects.

Dr Selim Cellek, who led the investigation as a collaborative work between UCL's Wolfson Institute for Biomedical Research and its Institute of Urology and Nephrology, said: "We are very excited by this discovery, as it is a medical breakthrough which represents a major advance in treating a condition that affects such a large proportion of the population. We are still at the development stages and more research will be required before the new treatment becomes available. The next step will be to develop links with investors interested in developing this drug for the treatment of BPH.

"Research has shown that this type of compound can also be used to treat erectile dysfunction (impotence). The future for this line of research is therefore promising since men with an enlarged prostate often suffer from impotence. "

Malcolm Grant, UCL Provost, said: "The conversion of scientific results into new medicines is one of the main aims of th
'"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-207-679-9728
University College London
27-Nov-2003


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Chronic pain treatments more effective when taken together, new study shows
4. Brain activity prior to treatment flags vulnerability to antidepressant side effects
5. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
6. OHSU scientists test medication to treat involuntary weight loss
7. Cultural and social factors influence prostate cancer treatment
8. Research offers hope of new treatments for liver damage
9. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
10. Risky surgery not always necessary to treat cervical disease
11. Stanford patient is first to test new treatment for peripheral arterial disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug treat enlarged prostate developed UCL

(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... 28, 2015 Pioneer Millworks reclaimed USA ... Architecture & Construction Materials Show, an annual, premier sustainable ... 1,000 suppliers and top manufacturers of the latest building ... products sourced and manufactured by Pioneer Millworks from ... in Japan at restaurants, hotels, retailers, and corporate offices. ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Dr. ... Central Coast area residents, recently announced a special offer ... It’s a treatment option for new and established patients ... 2015 with a bright, white smile, Dr. Patel and ... of $299, marked down from the regular price of ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 A ... federal testosterone lawsuits that have been filed by law ... the second week in March, the Firm notes. ... website, parties involved in the federal litigation will meet ... matters related to prescription therapy treatments designed to raise ...
(Date:2/28/2015)... 2015 How would you describe ... There are all kinds of different leaders, each ... of the advantages and applications of different leadership ... a new product this spring called The Leadership ... connection between personality type, leadership, and success. The ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
(Date:2/27/2015)... , February 27, 2015 ... new study showing you trends, R&D progress, and predicted ... heading? What are the commercial prospects for this ... you potential revenues and other trends to 2025, discussing ... report lets you assess regenerative medicine : cell-based ...
(Date:2/27/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its first quarter ended December 31, ... December 31, 2014, revenue was $1,336,685. Operating expenses were ... $0.02 per share.  Covalon,s President and ... pleased with the significant progress we have made over ...
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
Cached News: